An overview of the meningococcal disease and impact of the quadrivalent meningococcal conjugate vaccine
| Autor: | Asmaa Alrobai, Jehan Alrahimi, Sahar El Hadad |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Novel Research in Microbiology Journal, Vol 5, Iss 6, Pp 1463-1479 (2021) |
| Druh dokumentu: | article |
| ISSN: | 2537-0286 2537-0294 |
| DOI: | 10.21608/nrmj.2021.208181 |
| Popis: | Meningitis is an inflammation of the meninges, which are the three membranes that cover the brain and the spinal cord; which occurs when the fluid surrounding the meninges becomes infected. Meningitis is a life-threatening disease, particularly in older people and immunocompromised cases. The estimated annual numbers of meningitis cases in the industrialized countries are about 4-6 cases per 100,000 people. Meningococcal disease is caused by the bacterium Neisseria meningitides, which have A; C, Y, and W-135 serogroups. Immunization helps to protect the humans from infection, such as the meningococcal vaccine that protects from infection by A; C, Y, and W-135 serogroups. Meningococcal conjugate vaccines improve the immunogenicity potential, to prevent meningococcal disease. Several previous studies have documented the decrease in post-vaccination effectiveness induced by the meningococcal vaccines. However, effectiveness requires revaccination after a period of time from the first vaccination. The purposes of this article were to provide an overview of the meningitis disease, and demonstrate the effectiveness of the meningococcal conjugate vaccine. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|